IL292218B1 - Preparations for oral administration of active substances with a controlled absorption profile - Google Patents

Preparations for oral administration of active substances with a controlled absorption profile

Info

Publication number
IL292218B1
IL292218B1 IL292218A IL29221822A IL292218B1 IL 292218 B1 IL292218 B1 IL 292218B1 IL 292218 A IL292218 A IL 292218A IL 29221822 A IL29221822 A IL 29221822A IL 292218 B1 IL292218 B1 IL 292218B1
Authority
IL
Israel
Prior art keywords
active agent
therapeutically active
composition
range
protease inhibitor
Prior art date
Application number
IL292218A
Other languages
English (en)
Hebrew (he)
Other versions
IL292218A (en
IL292218B2 (en
Inventor
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Original Assignee
Entera Bio Ltd
Burshtein Gregory
Rothner Ariel
M Schwartz Phillip
GALITZER Hillel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd, Burshtein Gregory, Rothner Ariel, M Schwartz Phillip, GALITZER Hillel filed Critical Entera Bio Ltd
Publication of IL292218A publication Critical patent/IL292218A/en
Publication of IL292218B1 publication Critical patent/IL292218B1/en
Publication of IL292218B2 publication Critical patent/IL292218B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL292218A 2015-02-09 2016-02-09 Preparations for oral administration of active substances with a controlled absorption profile IL292218B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562113629P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
US201562113638P 2015-02-09 2015-02-09
US201562113604P 2015-02-09 2015-02-09
US201562113600P 2015-02-09 2015-02-09
US201562113619P 2015-02-09 2015-02-09
PCT/IL2016/050153 WO2016128972A1 (en) 2015-02-09 2016-02-09 Formulations for oral administration of active agents with controlled absorption profile

Publications (3)

Publication Number Publication Date
IL292218A IL292218A (en) 2022-06-01
IL292218B1 true IL292218B1 (en) 2024-06-01
IL292218B2 IL292218B2 (en) 2024-10-01

Family

ID=56614456

Family Applications (7)

Application Number Title Priority Date Filing Date
IL303216A IL303216A (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL292218A IL292218B2 (en) 2015-02-09 2016-02-09 Preparations for oral administration of active substances with a controlled absorption profile
IL283258A IL283258B2 (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL253802A IL253802B (en) 2015-02-09 2016-02-09 A preparation for the treatment of osteoporosis
IL292417A IL292417B1 (en) 2015-02-09 2016-02-09 A preparation for the treatment of osteoporosis
IL253803A IL253803B (en) 2015-02-09 2017-08-02 A preparation for the treatment of hypothyroidism
IL253804A IL253804B (en) 2015-02-09 2017-08-02 Preparations for oral administration of active substances with a controlled absorption profile

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL303216A IL303216A (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL283258A IL283258B2 (en) 2015-02-09 2016-02-09 A preparation for the treatment of hypothyroidism
IL253802A IL253802B (en) 2015-02-09 2016-02-09 A preparation for the treatment of osteoporosis
IL292417A IL292417B1 (en) 2015-02-09 2016-02-09 A preparation for the treatment of osteoporosis
IL253803A IL253803B (en) 2015-02-09 2017-08-02 A preparation for the treatment of hypothyroidism
IL253804A IL253804B (en) 2015-02-09 2017-08-02 Preparations for oral administration of active substances with a controlled absorption profile

Country Status (9)

Country Link
US (7) US20180050096A1 (ja)
EP (5) EP3256114A4 (ja)
JP (6) JP6925969B2 (ja)
CN (5) CN107427481A (ja)
CA (5) CA2975710C (ja)
HK (5) HK1247823A1 (ja)
IL (7) IL303216A (ja)
MX (2) MX2017010220A (ja)
WO (5) WO2016128974A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
WO2016128974A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents
CN116850132A (zh) * 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AU2020342512A1 (en) * 2019-09-03 2022-03-31 Amgen Inc. IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
WO2023161938A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
WO2023161939A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof
IL315200A (en) * 2022-02-24 2024-10-01 Entera Bio Ltd Preparations containing polymers that neutralize acidity for oral administration of GLP-2
WO2023161935A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
WO2023161933A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2023161934A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of active agents

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2003045331A2 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2010020978A1 (en) * 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2013189988A1 (en) * 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) * 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
CN1162917A (zh) * 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物,用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) * 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
CA2290443A1 (en) 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Peptide parathyroid hormone analogs
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
CA2364849A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL145546A0 (en) 1999-04-05 2002-06-30 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
IL149336A0 (en) 1999-11-05 2002-11-10 Emisphere Tech Inc Phenyl amine carboxylic acid compounds and compositions for delivering active agents
MXPA02006443A (es) * 1999-12-28 2002-11-29 Ajinomoto Kk Preparaciones orales para diabetes.
PT1420827E (pt) * 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide
EP1453816B1 (en) 2001-11-13 2013-09-18 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
AU2002354497A1 (en) 2001-12-19 2003-06-30 Sanwa Kagaku Kenkyusho Co., Ltd Release control type formed product
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口dds製剤
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060078622A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
CA2588418C (en) 2004-11-19 2015-06-02 Smithkline Beecham Corporation Pharmaceutical product providing a plurality of components
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007121471A2 (en) 2006-04-18 2007-10-25 Emisphere Technologies, Inc. Dialkyl ether delivery agents
US8019481B2 (en) * 2006-12-12 2011-09-13 Horiba Stec, Co., Ltd. Flow rate ratio control device
JP2010523554A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド タクロリムスの医薬組成物
EP2152244B1 (en) 2007-04-26 2015-12-02 Technion Research & Development Foundation Ltd. Oral administration of proteins and peptides
EP2200592A2 (en) * 2007-09-11 2010-06-30 Orahealth Corporation Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US20130138221A1 (en) 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
EP2747563A4 (en) 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2016128974A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2003045331A2 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2010020978A1 (en) * 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
WO2012080471A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2013189988A1 (en) * 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent

Also Published As

Publication number Publication date
CN113713090B (zh) 2023-06-02
EP3256149A1 (en) 2017-12-20
CA3011657A1 (en) 2016-08-18
CN114949185A (zh) 2022-08-30
IL292417A (en) 2022-06-01
HK1247838A1 (zh) 2018-10-05
EP3256114A1 (en) 2017-12-20
MX2022014313A (es) 2022-12-07
US20180050096A1 (en) 2018-02-22
EP3256114A4 (en) 2018-11-21
JP2023055902A (ja) 2023-04-18
EP3256113A4 (en) 2018-11-14
JP7275207B2 (ja) 2023-05-17
IL253803A0 (en) 2017-09-28
CA2975578A1 (en) 2016-08-18
WO2016128971A1 (en) 2016-08-18
IL283258A (en) 2021-07-29
IL253804A0 (en) 2017-09-28
EP3256153A1 (en) 2017-12-20
EP3256113A1 (en) 2017-12-20
IL253803B (en) 2021-06-30
HK1247835A1 (zh) 2018-10-05
US20200138913A1 (en) 2020-05-07
US20180036382A1 (en) 2018-02-08
IL283258B1 (en) 2023-07-01
WO2016128973A1 (en) 2016-08-18
CN113730556A (zh) 2021-12-03
IL292417B1 (en) 2024-08-01
JP2018504444A (ja) 2018-02-15
CN113713090A (zh) 2021-11-30
CA2975710C (en) 2023-08-08
WO2016128970A1 (en) 2016-08-18
WO2016128974A1 (en) 2016-08-18
IL283258B2 (en) 2023-11-01
BR112017017112A2 (pt) 2018-04-03
IL292218A (en) 2022-06-01
US20180028622A1 (en) 2018-02-01
IL253802B (en) 2022-06-01
JP2023100920A (ja) 2023-07-19
IL253804B (en) 2022-05-01
US20180021272A1 (en) 2018-01-25
EP3256152A4 (en) 2018-11-14
US20180036234A1 (en) 2018-02-08
EP3256153A4 (en) 2018-11-21
EP3256149A4 (en) 2019-08-14
CA2975710A1 (en) 2016-08-18
JP2021176913A (ja) 2021-11-11
US10583177B2 (en) 2020-03-10
CN107427481A (zh) 2017-12-01
IL303216A (en) 2023-07-01
CN113694190A (zh) 2021-11-26
CA3011654A1 (en) 2016-08-18
JP6925970B2 (ja) 2021-08-25
CN113694190B (zh) 2024-05-07
HK1247843A1 (zh) 2018-10-05
HK1247822A1 (zh) 2018-10-05
IL292218B2 (en) 2024-10-01
HK1247823A1 (zh) 2018-10-05
JP6925969B2 (ja) 2021-08-25
JP2018504445A (ja) 2018-02-15
CA2975676A1 (en) 2016-08-18
US12076373B2 (en) 2024-09-03
MX2017010220A (es) 2018-02-21
US20240181020A1 (en) 2024-06-06
JP2021176914A (ja) 2021-11-11
IL253802A0 (en) 2017-09-28
WO2016128972A1 (en) 2016-08-18
EP3256152A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
US12076373B2 (en) Formulations for oral administration of active agents
AU2017311698B2 (en) Formulations for oral administration of active agents
EP3197913B1 (en) Alpha-1 anti-trypsin for treating liver diseases
IL312219A (en) DSG2 preparations and methods